| Net loss | -70.23M |
| Depreciation and accretion | 2.15M |
| Amortization of intangible assets | 11.98M |
| Stock-based compensation | 9.6M |
| Interest expense on debt | |
| Amortization of loan agreement costs | |
| Non-cash foreign currency remeasurement (gain)/loss | 705K |
| Impairment of prepaid royalties and guarantees | |
| Changes in allowance for doubtful accounts | |
| Accounts receivable | 3.75M |
| Prepaid royalties | |
| Prepaid expenses and other assets | -1.15M |
| Accounts payable | 674K |
| Other accrued liabilities | |
| Accrued compensation | 2.25M |
| Accrued royalties | 748K |
| Deferred revenues | 1.31M |
| Accrued restructuring charge | 40K |
| Other long-term liabilities | |
| Net cash (used in)/provided by operating activities | |
| Purchase of property and equipment | -1.7M |
| Net cash used in investing activities | |
| Proceeds from line of credit | |
| Payments on line of credit | |
| Net proceeds from Public Offering | |
| MIG loan payments | |
| Proceeds from exercise of warrants and issuance of common stock | |
| Proceeds from exercise of stock options and ESPP | 2.16M |
| Net cash provided by/(used in) in financing activities | |
| Effect of exchange rate changes on cash | -263K |
| Net increase/(decrease) in cash and cash equivalents | -33.03M |
| Cash and cash equivalents at beginning of period | 180.54M |
| Cash and cash equivalents at end of period | 147.52M |